Replies to post #163979 on Biotech Values

[oc631]

The idea of bringing a questionable oral combo to market, without an interferon-based option (which can only be superior in efficacy), makes no sense.

In hindsight GILD is trying to do this in the U.S. with Sofo/Riba in GT3. Why not Russia?

[DewDiligence]

GILD—Russia doesn’t require the same level of evidence for drug approvals as the US, EU, Japan, and China (among others). Russia is rather more like India, where the supporting data can be scant.

Exhibit ‘A’ for Russia’s approval of a drug based on weak evidence: AGEN’s Oncophage (#msg-28291851).